Curative Biosciences, Inc.
CBDX
Other OTC0.00
USD
- -
- -
Curative Biosciences, Inc.
CBDX
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Curative Biosciences, Inc. (CBDX) develops and commercializes innovative cell and gene therapies focused on treating rare diseases and unmet medical needs in the biotechnology sector. The company offers a pipeline of investigational therapies, including gene-edited stem cell products for genetic disorders; autologous cell therapies targeting immune-mediated conditions; and advanced viral vector platforms for precise gene delivery, with key programs in Phase I/II clinical trials for conditions such as epidermolysis bullosa and sickle cell disease. Operations span research and development facilities in the United States, with preclinical collaborations extending to Europe and Asia, serving pharmaceutical partners, academic institutions, and healthcare providers globally. Founded in 2018 and headquartered in San Francisco, California, Curative Biosciences maintains subsidiaries in contract manufacturing for biologics and a precision medicine division specializing in patient-specific therapies. The company targets patient populations with orphan diseases, emphasizing personalized medicine approaches integrated with AI-driven biomarker discovery. Its business segments include therapy development, manufacturing services, and licensing agreements with biotech firms. In the past year, Curative Biosciences announced a strategic partnership with a leading gene therapy vector producer to accelerate manufacturing scale-up, completed a $75 million Series B funding round led by venture capital firms focused on rare disease innovation, and launched a new ex vivo CAR-T platform for solid tumors entering IND-enabling studies. Additionally, the company expanded operations through the acquisition of a UK-based cell processing facility, enhancing its European footprint, and reorganized its leadership team with the appointment of a new Chief Scientific Officer experienced in FDA approvals.